An item in BioWorld Today, Jan. 12, 2011, should have stated that Astex Therapeutics Ltd., of Cambridge, UK, received an undisclosed milestone payment from Novartis AG triggered by the initiation of a clinical trial of LEE011, an oncology candidate being developed by the companies under a 2005 collaboration aimed at cell cycle inhibitors. The deal called for three compounds and could bring Astex total payments of $520 million.

Editor's note: The correction has been made in BioWorld Online.

No Comments